# US 10,500,206 B2 · Method for enhancing wound healing by administrating adenine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,206 B2
- Document ID: US10500206B2
- Status: Granted
- Kind: B2
- Application number: 15/456,815
- Filed: 2017-03-13
- Published: 2018-09-13
- Granted: 2019-12-10
- Earliest claimed: 2017-03-13
- Assignees: Energenesis Biomedical Co., Ltd.
- Applicants: Energenesis Biomedical Co., Ltd.
- Inventors: Han-Min Chen; Cheng-Yi Kuo; Chun-Fang Huang; Jiun-Tsai Lin
- Web page: https://patentgrep.com/patent/US10500206B2

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is a composition for wound healing, which includes adenine and a pharmaceutically acceptable salt thereof. Also provided is a method for enhancing wound healing in a subject in need thereof including administering to the subject the composition.

## Claims

### Claim 1

A method for enhancing healing of a wound in a subject in need thereof, comprising administering to the subject a composition comprising adenine and/or a pharmaceutically acceptable salt thereof in an effective amount to enhance the healing of the wound in the subject, wherein the adenine and/or the pharmaceutically acceptable salt thereof in the composition is in an amount of between 0.0001% and 0.05% by weight, provided that an amount of 0.05% is excluded, and wherein the adenine and/or the pharmaceutically acceptable salt thereof serves as the only active ingredient for the healing of the wound in the composition, and the wound is a chronic wound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the wound appears in at least one tissue of the subject selected from the group consisting of skin, mouth, gingiva, and corneal epithelium.

### Claim 3 (depends on 1)

The method of claim 1, wherein the chronic wound is selected from the group consisting of a diabetic ulcer, a venous ulcer, a pressure ulcer, a vasculitic ulcer, a mouth ulcer, an arterial ulcer, a sickle cell ulcer, a corticosteroid-induced wound, a burn and a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the diabetic ulcer is a diabetic foot ulcer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition activates adenosine 5′-monophosphate-activated protein kinase (AMPK) in the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition lowers inflammation in the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition promotes at least one of re-epithelialization and matrix deposition of the wound.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition suppresses fibroblast proliferation and prevents scar formation during the healing of the wound.

### Claim 9 (depends on 1)

The method of claim 1, wherein the adenine and/or the pharmaceutically acceptable salt thereof in the composition is in an amount of between 0.0001% and 0.02% by weight.

### Claim 10 (depends on 9)

The method of claim 9, wherein the adenine and/or the pharmaceutically acceptable salt thereof in the composition is in an amount of between 0.001% and 0.02% by weight.

### Claim 11 (depends on 10)

The method of claim 10, wherein the adenine and/or the pharmaceutically acceptable salt thereof in the composition is in an amount of between 0.005% and 0.02% by weight.

### Claim 12 (depends on 11)

The method of claim 11, wherein the adenine and/or the pharmaceutically acceptable salt thereof in the composition is in an amount of between 0.008% and 0.02% by weight.

### Claim 13 (depends on 12)

The method of claim 12, wherein the adenine and/or the pharmaceutically acceptable salt thereof in the composition is in an amount of between 0.01% and 0.02% by weight.

### Claim 14 (depends on 1)

The method of claim 1, wherein the adenine and/or the pharmaceutically acceptable salt thereof is administered to the subject through topical administration or systemic administration.

### Claim 15 (depends on 1)

The method of claim 1, wherein the composition is formulated in one form selected from the group consisting of a solution, a liniment, a lotion, a spray, an aerosol, an ointment, a foam, a cream, a gel, a paste, a patch, a glue, a film, an orabase, a powder, and a wound dressing.